A retrospective record review and assessment of cost of quetiapine use in a community psychiatric setting in the Sedibeng district of Gauteng

South African Journal of Psychiatry

Field Value
Title A retrospective record review and assessment of cost of quetiapine use in a community psychiatric setting in the Sedibeng district of Gauteng
Creator Robertson, Lesley J. Miot, Jacqui K. Janse van Rensburg, Bernard
Subject — Quetiapine; Bipolar Disorder
Description Background: With the revision of the National Essential Medicines List in South Africa, quetiapine is only available at the discretion of individual institutions in the public health sector. However, quetiapine is effective in managing all aspects of bipolar disorder, including preventative treatment of depressive episodes, and may be a cost-effective option in severe illness.Aim: To present the first retrospective review of quetiapine use in a peri-urban health district of South Africa, describing the patient profile, clinical response and prescribing patterns.Methods: The clinical files of all patients in Sedibeng District who received quetiapine over a defined 3-year period (2011–2013) were reviewed. A positive clinical response was defined as both symptomatic and functional improvement. Demographic and clinical characteristics of responders were compared with that of non-responders. Pre- and post-quetiapine scripts of the responders were audited and costed.Results: Patients who received quetiapine (n = 40) had chronic disabling illness, often with multiple medication trials and hospitalisations prior to quetiapine use. Bipolar II disorder (followed by bipolar I disorder) was the most common primary psychiatric diagnosis documented. Other than improvement in functioning (p 0.0001), responders differed significantly from non-responders in terms of a higher level of polypharmacy and a significant reduction in median number of medications from pre- to post-quetiapine (p = 0.0057).Conclusion: Quetiapine use was associated with a highly significant improvement in functioning; however, it came at a 52% increase in medicine cost. Pre-quetiapine treatments, though, did not achieve an optimal level of functioning, and overall costs may be reduced by more rational prescribing habits.
Publisher AOSIS
Date 2017-07-17
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip application/xml application/pdf
Identifier 10.4102/sajpsychiatry.v23i0.1057
Source South African Journal of Psychiatry; Vol 23 (2017); 8 pages 2078-6786 1608-9685
Language eng
Relation https://sajp.org.za/index.php/sajp/article/view/1057/927 https://sajp.org.za/index.php/sajp/article/view/1057/926 https://sajp.org.za/index.php/sajp/article/view/1057/928 https://sajp.org.za/index.php/sajp/article/view/1057/916
Coverage — — —
Rights Copyright (c) 2017 Lesley J. Robertson, Jacqui K. Miot, Bernard Janse van Rensburg https://creativecommons.org/licenses/by/4.0